Read more about Rucaparib Receives Breakthrough Therapy Designation from FDA
Apr 14, 2015
Rucaparib Receives Breakthrough Therapy Designation from FDA
...of platinum-sensitive ovarian cancer, specifically in patients with tumors that have BRCA mutations and other DNA deficiencies commonly referred to as “BRCA-like.” An FDA-designated “breakthrough therapy” is a drug to...